Challenges and Recent Developments in Addressing Heterogeneity of Treatment Effects
Challenges and Recent Developments in Addressing Heterogeneity of Treatment Effects (301179)
Erik Bloomquist, FDA
*Erik Bloomquist, FDA
Keywords: Oncology
Following the talks, Dr. Erik Bloomquist from CDER/FDA will give a short discussion on each of the talks and also provide a regulatory perspective on how heterogeneous treatment effects are evaluated and considered.
